Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time

Princeton, New Jersey, November 30, 2021/PRNewswire/ - Guerbet LLC, the US subsidiary of Guerbet, a global leader in medical imaging, announced the recent boom in DOTAREM® (Gadolinium Meglumine) injections. In the face of ongoing pandemics and supply chain disruptions, DOTAREM has grown significantly. Since its release in the US in 2013, the company's flagship MRI contrast agent doses shipped in October have exceeded any other monthly period.

"Our flagship product has made great strides in the United States," said Thomas McLaughlin, vice president of North America. "DOTAREM is a trusted solution that supports our commitment to radiologists in the MR suite. There is no doubt that our macrocyclic and ionic molecules have the highest dynamic and thermodynamic stability among currently approved GBCAs."

Since its release in 1989, DOTAREM (gadolinium meglumine) injection has been the leading MR contrast agent in Europe, Asia, Africa, the Middle East and South America. DOTAREM was approved by the U.S. Food and Drug Administration (FDA) in 2013 and became the first macrocyclic ion gadolinium contrast agent (GBCA) in the United States. It has become the second largest magnetic resonance contrast agent in the United States and is currently the world's first, providing more than 120 million doses in 70 countries.

The news of DOTAREM's success comes after Guerbet's long tradition in radiology. During the 2020 COVID-19 crisis, the company mobilized partners and colleagues across the industry to continue to provide treatment-critical products to healthcare professionals. In addition, the organization continues to support the industry through research, education, and development, just as they participate in the annual Radiological Society of North America (RSNA) meeting.

For information about DOTAREM, please visit https://www.guerbet.com/en-us/products-solutions/contrast-agents/dotarem-gadoterate-meglumine-injection/.

At Guerbet, we build lasting relationships so that people can live better lives. This is our purpose. We are a global leader in the field of medical imaging, providing a wide range of medical products, medical equipment, digital and artificial intelligence solutions for diagnostic and interventional imaging. As a pioneer in the field of contrast agents with more than 2,600 employees worldwide for 95 years, we continue to innovate, spend 10% of our revenue on research and development, and have four centers in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (sector B-mid-cap stocks) and has revenue of 712 million euros in 2020. For more information, please visit www.guerbet-us.com.

Important safety information for DOTAREM® (Gadolinium meglumine) injection

Warning: Nephrogenic Systemic Fibrosis (NSF)

Gadolinium contrast agents (GBCA) increase the risk of NSF in patients with impaired drug clearance. Avoid using GBCA in these patients unless diagnostic information is essential and cannot be obtained by non-contrast MRI or other means. NSF can cause fatal or debilitating fibrosis, affecting the skin, muscles, and internal organs.

Indications and usage DOTAREM® (gadolinium meglumine) injection is a prescription gadolinium contrast agent, which is suitable for magnetic resonance imaging of the brain (intracranial), spine and related tissues of adults and children (including full-term newborns). MRI) intravenous injection to detect and visualize areas of blood-brain barrier (BBB) ​​damage and/or vascular abnormalities.

Contraindications have a history of clinically important hypersensitivity to DOTAREM.

We encourage you to report the side effects of prescription drugs to the FDA. Please visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please refer to complete prescribing information, including patient medication guidelines, for other important safety information. 

Reference: Dotarem [Package Insert]. Princeton, New Jersey: Guerbet LLC; October 2019.

More news releases on similar topics

Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time